In Vitro Removal of Beta‐2‐Microglobulin From Uremic Blood With an Immunoadsorption Wall

Abstract

Dialysis-related amyloidosis (DRA), caused by the accumulation of beta-2-microglobulin (β-2M), remains a major concern in long-term renal replacement therapies. For years, we have developed an immunoadsorption wall (iWall) for the removal of β-2M. In this study, we employed a new approach taking advantage of the melting of a buffer ice rod to improve the conditions associated with the manufacturing of an iWall and tested its performance with uremic serum and blood. The preliminary results reveal that the present iWalls thus prepared not only possess the superior properties of affinity and specificity but also show structural stability and acceptable hemocompatibility. We believe that this breakthrough might provide a promising path to successful treatment of DRA as well as establish a useful platform for studying removal of certain pathological toxins accumulated in the blood.

Artificial Organs 2012: A Year in Review

“…Tsung‐Hua Yang et al. of Cheng Shiu University, Kaohsiung, Taiwan reported on the development of an immunoadsorbent for removal of beta‐2‐microglobulin (β‐2M) in dialysis‐related amyloidosis. In vitro studies with uremic blood showed very good removal.…”